Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15211575 | 0.88 | NR4A2 (0.58) | POLBSLC26A4NR4A2NR4A1NR4A3 | |
| SCHEMBL15211552 | 0.84 | POLB (0.51) | POLBSLC26A4NR4A2NR4A1NR4A3 | |
| SCHEMBL15211619 | 0.80 | POLB (0.52) | POLBSLC26A4NR4A2NR4A1NR4A3 | |
| SCHEMBL15211617 | 0.80 | PPARD (0.63) | POLBSLC26A4NR4A2NR4A1NR4A3 | |
| SCHEMBL17431469 | 0.79 | MTNR1A (0.57) | POLBSLC26A4NR4A2PPARDPPARA | |
| SCHEMBL17431378 | 0.79 | POLB (0.53) | POLBSLC26A4NR4A2NR4A1NR4A3 | |
| SCHEMBL15211605 | 0.78 | MAOB (0.58) | POLBKMT2AMAOBMAOAMEN1 | |
| SCHEMBL17431376 | 0.78 | TDP1 (0.46) | POLBSLC26A4NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL17431343 | 0.78 | TDP1 (0.46) | POLBSLC26A4NR4A2KMT2ASMN1; SMN2 | |
| SCHEMBL10397860 | 0.76 | NR4A2 (0.72) | POLBSLC26A4NR4A2NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838891-B1 | AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-9238639-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150119407-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-04-30 | — | — | US | disclosed |
| EP-2838891-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013125732-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119407-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, SLC10A1, HPRT1 | POLB 3450/4885SLC26A4 77/4885NR4A2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.